315 related articles for article (PubMed ID: 25402233)
1. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
2. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS; 2014 Nov; 28(17):2625-7. PubMed ID: 25102089
[TBL] [Abstract][Full Text] [Related]
3. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
[TBL] [Abstract][Full Text] [Related]
4. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
5. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
[TBL] [Abstract][Full Text] [Related]
7. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Collins C; Shen DD; Collier AC; Ho RJ
AIDS; 2017 Mar; 31(6):765-770. PubMed ID: 28099191
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
9. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques.
Kinman L; Bui T; Larsen K; Tsai CC; Anderson D; Morton WR; Hu SL; Ho RJ
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):155-61. PubMed ID: 16760797
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
11. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.
Duan J; Freeling JP; Koehn J; Shu C; Ho RJ
J Pharm Sci; 2014 Aug; 103(8):2520-9. PubMed ID: 24948204
[TBL] [Abstract][Full Text] [Related]
13. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
14. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
15. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
16. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
[TBL] [Abstract][Full Text] [Related]
17. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
HIV Clin Trials; 2008; 9(4):238-46. PubMed ID: 18753118
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
[TBL] [Abstract][Full Text] [Related]
19. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.
Ravi PR; Vats R; Dalal V; Murthy AN
J Pharm Pharmacol; 2014 Jul; 66(7):912-26. PubMed ID: 24697749
[TBL] [Abstract][Full Text] [Related]
20. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
